BetterLife Pharma Inc.

BetterLife Pharma Inc. is a biopharmaceutical company engaged in developing patented pharmaceuticals. Its candidate pipeline includes BETR-001, an orally administered non-hallucinogenic lysergic acid diethylamide derivative molecule under preclinical development for mental health and neurological conditions like major depressive disorder, anxiety disorder, and neuropathic pain. The company is designing BETR-001 to be prescribed by psychiatrists and self-administered by patients. Through its subsidiary MedMelior Inc., the company also develops recombinant human interferon alpha-2b formulations: MM-001, a clinical-stage topical cream intended as a non-invasive self-administered therapy for human papillomavirus-induced cervical intraepithelial neoplasia, and MM-003, a preclinical inhaled formulation under development for respiratory viral infections.

The company operates through subsidiaries located in Canada, Australia, and Hong Kong, including MedMelior Inc., Blife Therapeutics Inc., Altum Pharma (Australia) Pty Ltd., and Altum Pharmaceuticals (HK) Limited. It maintains no internal manufacturing facilities, relying instead on third-party contract development and manufacturing organizations for product research, development, and production. The company leases its head office in Vancouver, British Columbia, Canada.

Summary of the business section of BetterLife Pharma's latest annual report, written by StockData.

“The following table sets forth the name, positions held and principal occupation of each of our directors, senior management and employees upon whose work the Company is dependent. Information on such persons’ share ownership is under Item 7. … Doug Drysdale (56)”